Universität zu Köln

Kessler, Carolina, von Brandenstein, Melanie ORCID: 0000-0002-1499-7644, Klümper, Niklas, Krausewitz, Philipp, Storz, Enno ORCID: 0009-0002-8250-5522, Rieger, Constantin ORCID: 0009-0000-3993-7974, Sperber, Laurenz, Paffenholz, Pia ORCID: 0000-0002-8209-7795, Tolkach, Yuri ORCID: 0000-0001-5239-2841, Wirtz, Ralph, Eckstein, Markus, Heidenreich, Axel ORCID: 0000-0002-2511-3664 and Weiten, Richard ORCID: 0009-0002-7216-1033 (2025). TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy. World Journal of Urology, 43 (1). pp. 1-8. Springer Nature. ISSN 1433-8726

Rieger, Constantin ORCID: 0009-0000-3993-7974, Schlüchtermann, Jörg ORCID: 0009-0004-2366-3584, Heidenreich, Julian ORCID: 0009-0001-7556-7445, Steenbock, Olivia ORCID: 0009-0002-7208-8104, Schmid, Florian A. ORCID: 0000-0002-0862-5027, Weiten, Richard ORCID: 0009-0002-7216-1033, Bach, Christian, Pfister, David ORCID: 0000-0002-2109-3221 and Heidenreich, Axel ORCID: 0000-0002-2511-3664 (2025). Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany. European Journal of Cancer, 227. pp. 1-7. Elsevier. ISSN 09598049

Rieger, Constantin ORCID: 0009-0000-3993-7974, Hübers, Max ORCID: 0000-0002-6237-3326, Kastner, Lucas ORCID: 0000-0001-5839-5461, Pfister, David ORCID: 0000-0002-2109-3221, Holling, Heinz and Heidenreich, Axel ORCID: 0000-0002-2511-3664 (2023). Center-based First-line Therapy Is a Significant Predictor for Mortality of Fournier Gangrene. JU Open Plus, 1 (7). e00031. American Urological Association, Education and Research. ISSN 2771-554X

Steenbock, Olivia ORCID: 0009-0002-7208-8104, Paffenholz, Pia ORCID: 0000-0002-8209-7795, Rieger, Constantin ORCID: 0009-0000-3993-7974, Heidenreich, Julian ORCID: 0009-0001-7556-7445, Pfister, David ORCID: 0000-0002-2109-3221, von Brandenstein, Melanie ORCID: 0000-0002-1499-7644 and Heidenreich, Axel ORCID: 0000-0002-2511-3664 (2025). NGS-basierte („next generation sequencing“) molekulare Panelanalyse des metastasierten Prostatakarzinoms: Wie häufig finden wir therapierbare Mutationen? Die Urologie, 64 (3). pp. 256-268. Springer Nature. ISSN 2731-7064